RomoloTavani AbbVie Inc. (NYSE:ABBV) investors must wonder what it must take for market participants to move past the company’s Humira headwinds to focus on its ex-Humira growth products instead. Therefore, I’m pleasantly surprised with the announcement earlier today that AbbVie will acquire Immunogen (IMGN) for about $10B in cash. AbbVie will pay a price of…
mphillips007 Martin Wolf, writer for the Financial Times, has warned us: “Painful fiscal choices seem to lie ahead.” Public debt has reached high levels when compared with the past. Mr. Wolf reports that the IMF has shown that in 2023 the ratio of public debt in high-income countries reached 112 percent. This is down from…
Spencer Platt/Getty Images News The market does not always react the way that one might anticipate. Sometimes, positive results relative to expectations can result in upside, while in other cases it can lead to downside. The exact same thing can be said of negative results. A great example of this can be seen by looking…